Presentation is loading. Please wait.

Presentation is loading. Please wait.

Elevated IgE and atopy in patients treated for early-onset ADA-SCID

Similar presentations


Presentation on theme: "Elevated IgE and atopy in patients treated for early-onset ADA-SCID"— Presentation transcript:

1 Elevated IgE and atopy in patients treated for early-onset ADA-SCID
Monica G. Lawrence, MD, John S. Barber, BA, Robert A. Sokolic, MD, Elizabeth K. Garabedian, RN, MSLS, Avanti N. Desai, MS, Michelle O'Brien, RN, BSN, Nina Jones, RN, BSN, Pawan Bali, PhD, Michael S. Hershfield, MD, Kelly D. Stone, MD, PhD, Fabio Candotti, MD, Joshua D. Milner, MD  Journal of Allergy and Clinical Immunology  Volume 132, Issue 6, Pages e5 (December 2013) DOI: /j.jaci Copyright © Terms and Conditions

2 Fig 1 Percentage of IL-4+ or IL-13+ central memory CD4+ cells from healthy donors (n = 16) versus donors with ADA-SCID (n = 12) (A) and atopic (n = 7) versus nonatopic (n = 5) patients with ADA-SCID (B). C, Percentage of CD69+CD98+CD4+ cells following stimulation with staphylococcal enterotoxin B (SEB) in healthy donors (n = 14) versus donors with ADA-SCID (n = 7). ns, Nonsignificant. *P < .05, **P < .01, and ***P < .001. Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © Terms and Conditions

3 Fig E1 Percentage of IL-4+ or IL-13+ effector memory (EM) CD4+ cells from healthy donors (n = 16) versus donors with ADA-SCID (n = 12) (A) and atopic (n = 7) versus nonatopic (n = 5) patients with ADA-SCID (B). C, Percentage of IFN-γ+ EM and central memory (CM) CD4+ cells from healthy donors (n = 5) versus donors with ADA-SCID (n = 17). D, Percentage of IL-4+ and IL-13+ CD8+ cells from healthy donors (n = 16) versus donors with ADA-SCID (n = 12). ns, Nonsignificant. *P < .05 and **P < .01. Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © Terms and Conditions

4 Fig E2 A, Percentage of CD4+CD45RO+FoxP3+ cells in healthy donors (n = 13) versus donors with ADA-SCID (n = 11). B, Percentage of CD4+CD45RO+FoxP3+ cells in healthy donors (n = 13) versus atopic (n = 7) and nonatopic (n = 4) patients with ADA-SCID. C, Representative FACS plot demonstrating lack of abnormal TH2 cytokine production by CD4+CD45RO+FoxP3+ cells in a healthy donor (top) versus patient ADA12 (bottom). A similar lack of cytokine production was noted in all patients and controls tested. FACS, Fluorescence-activated cell sorting; ns, nonsignificant. Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © Terms and Conditions

5 Fig E3 A, Percentage of CD69+CD98+CD4+ cells following stimulation with anti-CD3 and anti-CD28 in healthy donors (n = 11) versus donors with ADA-SCID (n = 6). B and C, Level of activation (CD69+CD98+) in response to stimulation with staphylococcal enterotoxin B (SEB) versus percentage of TH2 cytokine (IL-4 and/or IL-13) positive (Fig E3, B) central memory CD4+ cells and (Fig E3, C) effector memory CD4+ cells. *P < .05. Journal of Allergy and Clinical Immunology  , e5DOI: ( /j.jaci ) Copyright © Terms and Conditions


Download ppt "Elevated IgE and atopy in patients treated for early-onset ADA-SCID"

Similar presentations


Ads by Google